BMS, BioNTech partner on bispecific antibody in deal worth up to $11.1bn

Retrieved on: 2025-06-04 16:56:35

Tags for this article:

Click the tags to see associated articles and topics

BMS, BioNTech partner on bispecific antibody in deal worth up to $11.1bn. View article details on hiswai:

Excerpt

Bristol Myers Squibb (BMS) and BioNTech have announced a strategic partnership to codevelop and commercialize BNT327, a bispecific antibody ...

Article found on: www.bioprocessintl.com